Proliferative changes in the bronchial epithelium of former smokers treated with retinoids

J Natl Cancer Inst. 2007 Nov 7;99(21):1603-12. doi: 10.1093/jnci/djm205. Epub 2007 Oct 30.

Abstract

Background: Retinoids have shown antiproliferative and chemopreventive activity. We analyzed data from a randomized, placebo-controlled chemoprevention trial to determine whether a 3-month treatment with either 9-cis-retinoic acid (RA) or 13-cis-RA and alpha-tocopherol reduced Ki-67, a proliferation biomarker, in the bronchial epithelium.

Methods: Former smokers (n = 225) were randomly assigned to receive 3 months of daily oral 9-cis-RA (100 mg), 13-cis-RA (1 mg/kg) and alpha-tocopherol (1200 IU), or placebo. Bronchoscopic biopsy specimens obtained before and after treatment were immunohistochemically assessed for changes in the Ki-67 proliferative index (i.e., percentage of cells with Ki-67-positive nuclear staining) in the basal and parabasal layers of the bronchial epithelium. Per-subject and per-biopsy site analyses were conducted. Multicovariable analyses, including a mixed-effects model and a generalized estimating equations model, were used to investigate the treatment effect (Ki-67 labeling index and percentage of bronchial epithelial biopsy sites with a Ki-67 index > or = 5%) with adjustment for multiple covariates, such as smoking history and metaplasia. Coefficient estimates and 95% confidence intervals (CIs) were obtained from the models. All statistical tests were two-sided.

Results: In per-subject analyses, Ki-67 labeling in the basal layer was not changed by any treatment; the percentage of subjects with a high Ki-67 labeling in the parabasal layer dropped statistically significantly after treatment with 13-cis-RA and alpha-tocopherol treatment (P = .04) compared with placebo, but the drop was not statistically significant after 9-cis-RA treatment (P = .17). A similar effect was observed in the parabasal layer in a per-site analysis; the percentage of sites with high Ki-67 labeling dropped statistically significantly after 9-cis-RA treatment (coefficient estimate = -0.72, 95% CI = -1.24 to -0.20; P = .007) compared with placebo, and after 13-cis-RA and alpha-tocopherol treatment (coefficient estimate = -0.66, 95% CI = -1.15 to -0.17; P = .008).

Conclusions: In per-subject analyses, treatment with 13-cis-RA and alpha-tocopherol, compared with placebo, was statistically significantly associated with reduced bronchial epithelial cell proliferation; treatment with 9-cis-RA was not. In per-site analyses, statistically significant associations were obtained with both treatments.

Publication types

  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural

MeSH terms

  • Adult
  • Aged
  • Alitretinoin
  • Anticarcinogenic Agents / therapeutic use*
  • Antineoplastic Agents / therapeutic use
  • Biomarkers / metabolism
  • Bronchi / drug effects*
  • Bronchi / immunology
  • Cell Proliferation / drug effects
  • Double-Blind Method
  • Female
  • Humans
  • Immunohistochemistry
  • Isotretinoin / therapeutic use*
  • Ki-67 Antigen / metabolism
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Research Design
  • Respiratory Mucosa / drug effects*
  • Respiratory Mucosa / immunology
  • Smoking Cessation*
  • Smoking*
  • Tretinoin / therapeutic use*
  • alpha-Tocopherol / therapeutic use*

Substances

  • Anticarcinogenic Agents
  • Antineoplastic Agents
  • Biomarkers
  • Ki-67 Antigen
  • Alitretinoin
  • Tretinoin
  • Isotretinoin
  • alpha-Tocopherol